Context-based sensing of orthosomycin antibiotics by the translating ribosome

Girolline is a sequence context-selective modulator of eIF5A activity

Natural products have a long history of providing probes into protein biosynthesis, with many of these compounds serving as therapeutics. The marine natural product girolline has been described as an inhibitor of protein synthesis. Its precise mechanism of action, however, has remained unknown. The data we present here suggests that girolline is a sequence-selective modulator of translation factor eIF5A. Girolline interferes with ribosome-eIF5A interaction and induces ribosome stalling where translational progress is impeded, including on AAA-encoded lysine. Our data furthermore indicate that eIF5A plays a physiological role in ribosome-associated quality control and in maintaining the efficiency of translational progress. Girolline helped to deepen our understanding of the interplay between protein production and quality control in a physiological setting and offers a potent chemical tool to selectively modulate gene expression.

Paenilamicins are context-specific translocation inhibitors of protein synthesis

The paenilamicins are a group of hybrid nonribosomal peptide-polyketide compounds produced by the honey bee pathogen Paenibacillus larvae that display activity against Gram-positive pathogens, such as Staphylococcus aureus. While paenilamicins have been shown to inhibit protein synthesis, their mechanism of action has remained unclear. Here we determine structures of paenilamicin PamB2-stalled ribosomes, revealing a unique binding site on the small 30S subunit located between the A- and P-site transfer RNAs (tRNAs). In addition to providing a precise description of interactions of PamB2 with the ribosome, the structures also rationalize the resistance mechanisms used by P. larvae. We further demonstrate that PamB2 interferes with the translocation of messenger RNA and tRNAs through the ribosome during translation elongation, and that this inhibitory activity is influenced by the presence of modifications at position 37 of the A-site tRNA. Collectively, our study defines the paenilamicins as a class of context-specific translocation inhibitors.

A chitosan-based hydrogel with ultrasound-driven immuno-sonodynamic therapeutic effect for accelerated bacterial infected wound healing

Sonodynamic therapy has attracted much attention as a noninvasive treatment for deep infections. However, it is challenging to achieve high antibacterial activity for hydrogels under ultrasonic irradiation due to the relatively weak sono-catalysis capability of sonosensitizers. Herein, an ultrasound-responsive antibacterial hydrogel (Fe3O4/HA/Ber-LA) composed of Fe3O4-grafted-Berberine, chitosan molecules modified with L-arginine and poly (vinyl alcohol) is prepared for enhanced sonodynamic therapy and immunoregulation. The formation of heterojunction between berberine and Fe3O4 with different work function promotes the charge separation and electron flow and disrupts the conjugated structure of berberine, causing a significant decrease in the band gap, eventually enhancing the sonocatalytic activity. The combination of berberine with Fe3O4 also significantly improves the oxygen adsorption energy, enabling more O2 molecules to react with the electron-rich regions on the surface of Fe3O4 to generate more reactive oxygen species (ROS). L-arginine grafted in the hydrogel is catalyzed by the ROS to release nitric oxide, which not only possesses antibacterial activity, but also positively affects macrophage M1 polarization to display potent phagocytosis to Staphylococcus aureus, thus achieving immuno-sonodynamic therapy. Hence, Fe3O4/HA/Ber-LA hydrogel under ultrasound irradiation shows excellent antibacterial activity. Furthermore, the antioxidative activity and anti-inflammatory effect of berberine released from the hybrid hydrogel induces macrophages to polarize towards the anti-inflammatory M2 status as infection comes under control, thus accelerating the wound healing. The hybrid hydrogel based on the immuno-sonodynamic therapy may be an extraordinary candidate for the treatment of deep infections.

Paenilamicins from the honey bee pathogen Paenibacillus larvae are context-specific translocation inhibitors of protein synthesis

The paenilamicins are a group of hybrid non-ribosomal peptide-polyketide compounds produced by the honey bee pathogen Paenibacillus larvae that display activity against Gram-positive pathogens, such as Staphylococcus aureus. While paenilamicins have been shown to inhibit protein synthesis, their mechanism of action has remained unclear. Here, we have determined structures of the paenilamicin PamB2 stalled ribosomes, revealing a unique binding site on the small 30S subunit located between the A- and P-site tRNAs. In addition to providing a precise description of interactions of PamB2 with the ribosome, the structures also rationalize the resistance mechanisms utilized by P. larvae. We could further demonstrate that PamB2 interferes with the translocation of mRNA and tRNAs through the ribosome during translation elongation, and that this inhibitory activity is influenced by the presence of modifications at position 37 of the A-site tRNA. Collectively, our study defines the paenilamicins as a new class of context-specific translocation inhibitors.

Ribosome-targeting antibiotics and resistance via ribosomal RNA methylation

The rise of multidrug-resistant bacterial infections is a cause of global concern. There is an urgent need to both revitalize antibacterial agents that are ineffective due to resistance while concurrently developing new antibiotics with novel targets and mechanisms of action. Pathogen associated resistance-conferring ribosomal RNA (rRNA) methyltransferases are a growing threat that, as a group, collectively render a total of seven clinically-relevant ribosome-targeting antibiotic classes ineffective. Increasing frequency of identification and their growing prevalence relative to other resistance mechanisms suggests that these resistance determinants are rapidly spreading among human pathogens and could contribute significantly to the increased likelihood of a post-antibiotic era. Herein, with a view toward stimulating future studies to counter the effects of these rRNA methyltransferases, we summarize their prevalence, the fitness cost(s) to bacteria of their acquisition and expression, and current efforts toward targeting clinically relevant enzymes of this class.